针对多发性骨髓瘤中的代谢重编程:分子机制和潜在的治疗点
Xueting Zhu1, Yikun Wang2, Yizi He3
1Graduate Collaborative Training Base of Hunan Cancer Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan,421001,China; Department of Lymphoma & Hematology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, No. 283 Tongzipo Road, Yuelu District, Changsha, Hunan, China.
多发性骨髓瘤 (MM) 细胞重新编程新陈代谢以推动进展和耐药性. 针对这些代谢脆弱性为MM患者提供了新的治疗和生物标志物策略.
科学领域:
- 血液恶性瘤研究研究
- 癌症新陈代谢 癌症新陈代谢
- 翻译性瘤学 翻译性瘤学
背景情况:
- 多发性骨髓瘤 (MM) 是一种血细胞恶性瘤,在治疗耐药性和复发方面存在持续的挑战.
- 代谢重编程是MM进展和药物耐药性的关键因素,不仅仅是能量生产.
- 骨髓微环境和治疗压力塑造了MM细胞代谢.
研究的目的:
- 系统地审查多发性骨髓瘤中代谢途径重新连接的分子机制.
- 探索相互连接的代谢网络在MM扩散,应激适应和免疫逃避中的作用.
- 突出代谢脆弱性作为MM的潜在治疗点和生物标志物.
主要方法:
- 关于多发性骨髓瘤代谢重编程的文献综述.
- 分析葡萄糖,脂质,氨基酸,核酸和微量元素代谢中的分子机制.
- 研究肠道微生物群对MM进展的影响.
主要成果:
- 主要代谢途径的异常激活维持了MM.
- 一个相互连接的代谢网络支持瘤生长,应激适应,免疫逃避和耐药性.
- 代谢状态提供了超越传统分期系统的功能信息.
结论:
- 代谢重编程是多发性骨髓瘤病原和治疗耐药性的核心.
- 代谢脆弱性代表了新疗法和生物标志物的可操作目标.
- 基于新陈代谢的策略对于改善MM治疗和风险分层至关重要.
更多相关视频
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
